BioSpace News Archive

Biotech Bay

Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock - Jan 25, 2023

Pacific Biosciences of California, Inc. announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share.

January 24, 2023
·
4 min read
Business

Vizient forms strategic partnership with MDsave to power its national direct-to-employer surgical-bundle solution

MDsave, the nation’s leading online healthcare services platform connecting providers, employers, and patients to transparent, transactable, and quality healthcare, announced today a strategic partnership with Vizient, Inc.

January 24, 2023
·
2 min read
Pharm Country

ENB Therapeutics to present at the 2023 BIO CEO & Investor and Immuno-Oncology 360o Conferences

ENB Therapeutics to present at the 2023 BIO CEO & Investor and Immuno-Oncology 360 Conferences.

January 24, 2023
·
4 min read
Biotech Beach

Biological Dynamics to deliver showcase presentation at Precision Medicine World Conference

Biological Dynamics’ Medical Director, Harmeet Dhani, MD, MSc to present data demonstrating clinical utility of the ExoVerita™ exosome-isolation platform for detection of early-stage cancers.

January 24, 2023
·
3 min read
Median Technologies to Host Two Webcasts and Provide a Company Update on February 2, 2023

Median Technologies (ALMDT:PA) (Paris:ALMDT) announced today that Fredrik Brag, CEO and founder of Median Technologies, will provide a company update on February 2nd.

January 24, 2023
·
1 min read
Lone Star Bio

Fabre-Kramer Pharmaceuticals Announces FDA Acceptance of NDA Resubmission as Complete Response and Assignment of PDUFA Regulatory Action Date

HOUSTON, Jan. 24, 2023 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals announced today it received on January 20, 2023 acknowledgement and acceptance of its December 23, 2022 NDA Amendment for EXXUA (gepirone hydrochloride) extended release tablets for the treatment of Major Depressive Disorder (MDD).

January 24, 2023
·
1 min read
Drug Development

VITRAC Therapeutics Initiates a Phase 1 Clinical Trial with the Aurora Kinase A Inhibitor VIC-1911 and G12C Inhibitor Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

VITRAC Therapeutics, LLC (VITRAC) initiated a Phase 1 Study of VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC).

January 24, 2023
·
3 min read
Business

InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Dr. Christopher Prior, as CEO and Reports Recent Drug Discovery Highlights

InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces the appointment of Dr. Christopher Prior as Chief Executive Officer.

January 24, 2023
·
3 min read
Drug Development

Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis

Precigen, Inc. (Nasdaq: PGEN) today announces positive Phase 1 dose escalation and expansion cohort data as of the January 12, 2023 cutoff for the investigational, potential first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse™ immunotherapy in patients with recurrent respiratory papillomatosis (RRP).

January 24, 2023
·
13 min read
Business

AbCellera to Report Full Year 2022 Financial Results on February 21, 2023

AbCellera (Nasdaq: ABCL) will announce its full year 2022 financial results on Tuesday, February 21, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

January 24, 2023
·
1 min read